Subscription of Piramal debentures by Canadian investor approved by CCI
The Competition Commission of India (CCI) in a tweet said it "approves the subscription of CCDs of Piramal Enterprises by CDPQ. Upon conversion, the equity shareholding of CDPQ in Piramal Enterprises will increase from 3.68 per cent to 8.99 per cent."
New Delhi: Fair trade regulator CCI on Tuesday said it has given nod to subscription of Piramal Enterprises' compulsory convertible debentures by Canadian institutional investor, Caisse de dépôt et placement du Québec (CDPQ).
The Competition Commission of India (CCI) in a tweet said it "approves the subscription of CCDs of Piramal Enterprises by CDPQ. Upon conversion, the equity shareholding of CDPQ in Piramal Enterprises will increase from 3.68 per cent to 8.99 per cent."
Piramal Enterprises in a regulatory filing in October said its board has approved raising of Rs 5,400 crore through a rights issue and preferential allotment of compulsory convertible debentures (CCDs).
"The rights issue of Rs 3,650 crore at Rs 1,300 per share, is intended to give an opportunity to all its existing shareholders to participate in the capital raise at an attractive price," Piramal Enterprises said in a filing to the BSE.
"In addition, the company plans to raise Rs 1,750 crore through the preferential allotment of CCDs at a conversion price of Rs 1,510 per share to Canadian institutional investor, Caisse de dépôt et placement du Québec (CDPQ)," Piramal Enterprises had said.
The preferential allotment will take place by November this year and the rights issue is expected to be completed by February 2020, it had added.
Read Also: Piramal Pharma, BerGenBio enter partnership for developing leukemia drug Bemcentinib
These funds will strengthen the company's balance sheet, insulate it against any external shocks and enable it to tap organic and inorganic opportunities arising out of market consolidation across our financial services, pharmaceuticals and information management businesses, Piramal Enterprises Chairman Ajay Piramal had said.
CDPQ has a long-standing partnership with Piramal Enterprises. It had participated as the anchor investor during its previous capital issuance, investing USD 175 million (around Rs 1,240 crore) out of the total issue size of USD 750 million, (over Rs 5,320 crore).
Read Also: Piramal Enterprises plans to raise upto Rs 1000 crore via NCDs
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd